Suppressing MAPK1, a mutated variant of the NF2-Ras signaling pathway, may increase the sensitivity of cancer cells to ferroptosis, which can eventually lead to targeted cell death in therapy-resistant cancers. This evidence concerns the gene NF2 and cancer.